Democrat Media in Full Collapse After Devastating Election Loss https://banned.video/watch?id=674f72b84888c518d34f8443

Tourette syndrome (TS) is a disabling neurodevelopmental disorder characterized by multiple, recurrent tics. The pharmacological treatment of TS is currently based on dopaminergic antagonists; however, these drugs are associated with extrapyramidal symptoms and other serious adverse events. Recent evidence suggests that positive allosteric modulators (PAMs) of GABAA receptors containing α6 subunits (α6 GABAARs) oppose the behavioral effects of dopamine. Building on this evidence, in the present study, we tested the efficacy of DK-I-56-1, a highly selective PAM for α6 GABAARs, in mouse models of TS exhibiting tic-related responses. DK-I-56-1 significantly reduced tic-like jerks and prepulse inhibition (PPI) deficits in D1CT-7 transgenic mice, a well-documented mouse model of TS. DK-I-56-1 also prevented the exacerbation of spontaneous eyeblink reflex induced by the potent dopamine D1 receptor agonist SKF 82958, a proxy for tic-like responses. We also showed that both systemic and prefrontal cortical administration of DK-I-56-1 countered the PPI disruption caused by SKF 82958. Although the effects of DK-I-56-1 were akin to those elicited by dopaminergic antagonists, this drug did not elicit extrapyramidal effects, as measured by catalepsy. These results point to α6 GABAAR PAMs as promising TS therapies with a better safety profile than dopaminergic antagonists.(1) Background. Visceral adiposity index (VAI) has been recently identified as a new cardiometabolic risk marker reflecting abdominal fat distribution and dyslipidaemia. The aim of the present paper was to evaluate the relationship between VAI, daily energy intake and metabolic syndrome (MetS) in a cohort of obese Caucasian children and adolescents, aged 8 to 15 years. (2) Methods. Consecutive Italian children and adolescents with obesity, according to World Health Organization were enrolled. Anthropometric parameters and blood pressure were measured. Fasting blood samples have been analyzed for lipids, insulin and glucose levels. MetS was diagnosed using identification and prevention of dietary- and lifestyle-induced health effects in children and infants (IDEFICS) or International Diabetes Federation (IDF) criteria according to age. Homeostatic model assessment index (HOMA-IR), quantitative insulin sensitivity check index (QUICKI), A body shape index (ABSI) and VAI were calculated. Multivariable logistic rescore but no association was found with VAI. (4) Conclusion. VAI is a promising tool to identify MetS in children and adolescents with obesity and should be used in the management of abdominal obesity together with dietary assessment.Epilepsy is one of the most common neurological disorders, and it is characterized by spontaneous seizures. In a previous study, we identified 4-(2-chloro-4-fluorobenzyl)-3-(2-thienyl)-1,2,4-oxadiazol-5(4H)-one (GM-90432) as a novel anti-epileptic agent in chemically- or genetically-induced epileptic zebrafish and mouse models. In this study, we investigated the anti-epileptic effects of GM-90432 through neurochemical profiling-based approach to understand the neuroprotective mechanism in a pentylenetetrazole (PTZ)-induced epileptic seizure zebrafish model. GM-90432 effectively improved PTZ-induced epileptic behaviors via upregulation of 5-hydroxytryptamine, 17-β-estradiol, dihydrotestosterone, progesterone, 5α -dihydroprogesterone, and allopregnanolone levels, and downregulation of normetanephrine, gamma-aminobutyric acid, and cortisol levels in brain tissue. GM-90432 also had a protective effect against PTZ-induced oxidative stress and zebrafish death, suggesting that it exhibits biphasic neuroprotective effects via scavenging of reactive oxygen species and anti-epileptic activities in a zebrafish model. In conclusion, our results suggest that neurochemical profiling study could be used to better understand of anti-epileptic mechanism of GM-90432, potentially leading to new drug discovery and development of anti-seizure agents.Container-based virtualization is becoming a de facto way to build and deploy applications because of its simplicity and convenience. Kubernetes is a well-known open-source project that provides an orchestration platform for containerized applications. An application in Kubernetes can contain multiple replicas to achieve high scalability and availability. Stateless applications have no requirement for persistent storage; however, stateful applications require persistent storage for each replica. Therefore, stateful applications usually require a strong consistency of data among replicas. To achieve this, the application often relies on a leader, which is responsible for maintaining consistency and coordinating tasks among replicas. This leads to a problem that the leader often has heavy loads due to its inherent design. In a Kubernetes cluster, having the leaders of multiple applications concentrated in a specific node may become a bottleneck within the system. In this paper, we propose a leader election algorithm that overcomes the bottleneck problem by evenly distributing the leaders throughout nodes in the cluster. We also conduct experiments to prove the correctness and effectiveness of our leader election algorithm compared with a default algorithm in Kubernetes.Tissue chips (TCs) and microphysiological systems (MPSs) that incorporate human cells are novel platforms to model disease and screen drugs and provide an alternative to traditional animal studies. This review highlights the basic definitions of TCs and MPSs, examines four major organs/tissues, identifies critical parameters for organization and function (tissue organization, blood flow, and physical stresses), reviews current microfluidic approaches to recreate tissues, and discusses current shortcomings and future directions for the development and application of these technologies. The organs emphasized are those involved in the metabolism or excretion of drugs (hepatic and renal systems) and organs sensitive to drug toxicity (cardiovascular system). https://www.selleckchem.com/products/pim447-lgh447.html This article examines the microfluidic/microfabrication approaches for each organ individually and identifies specific examples of TCs. This review will provide an excellent starting point for understanding, designing, and constructing novel TCs for possible integration within MPS.

***
Reposted
****
The FDA's War Against America's Health
****
https://www.lewrockwell.com/2024/11/no_author/the-fdas-war-against-americas-health/
****
For most of my life, I have observed the FDA belligerently suppress natural treatments and any unorthodox therapy which threatens the medical monopoly while simultaneously railroading through a variety of unsafe and ineffective drugs regardless of how much public protest the agency meets.

As such, I do not hold the FDA in a positive light, especially given that during COVID-19, I (like many others) spent hundreds of hours trying to get the agency to allow the limited use of off-patent therapeutics for COVID-19—all of which ultimately went nowhere due to the unjustifiable roadblocks the agency kept putting up.
Note: given my familiarity with the FDA’s conduct, I felt the odds were against those endeavors succeeding, but I nonetheless exhausted myself supporting effective alternative therapies because I didn’t want to live with the knowledge I could have done something that could have prevented the unfolding tragedy but chose not to.

Over the last year, and especially since Trump won the election, I have received a lot of inquiries as to how the FDA could be reformed over the next four years. Given the importance of presenting the issue correctly, I’ve spent a lot of time trying to look at both sides of the question.

In medicine, “sensitivity” denotes how likely a test is not to miss something that’s there, while “specificity” denotes how likely a test is not to have a false positive. The great challenge with these two concepts is that there’s almost always a trade-off. Hence, as you increase one, the other reciprocally declines (e.g., as the PCR cycle threshold was increased on COVID tests, while it was harder to miss an infection, you also became more and more likely to get false positives from the tests—which is frequently what happened). In turn, many issues in medicine result from a poor balance between the two (e.g., Peter C. Gøtzsche made a good case that the sensitivity for routine breast cancer screening is too high, which leads to many women being erroneously diagnosed with dangerous breast cancers and subject to unnecessary treatments).

This same trade-off also exists throughout politics as there are often two conflicting positions (e.g., wanting a robust death penalty to serve as a deterrent against violent crimes but also not wanting to execute innocent individuals), and in many cases the eventual position that’s settled on is the result of a prolonged battle that eventually reaches a midpoint between sensitivity and specificity that while not ideal, is begrudgingly acceptable to both sides. In my eyes, the most important thing to understand about this dynamic is that it typically takes an incredible amount of work to reach the functional compromise that’s eventually settled upon, so if the existing process is scrapped (e.g. because people who are polarized on the issue can only see it from their side’s perspective) what follows (e.g., a complete lack of police enforcement in high crime areas) is often much worse than what preceded it.

In the case of the FDA, the agency’s situation has run into a similar issue—the FDA is expected to keep bad foods and drugs off the market while not blocking good ones from getting to the public. While this seems “simple,” it’s actually an incredibly challenging task, and the agency’s history is one of it frequently abysmally failing at both—even when its leadership was composed of dedicated public servants who put the wellbeing of the American people before everything else.

Crime Against the Food Law

In the late 1800s, food producers would constantly sell adulterated food, while early pharmaceutical companies would sell a variety of proprietary medicines with secret ingredients that were inevitably things like opium and alcohol. Gradually, public outrage built around this, particularly since journalists and newspapers were willing to expose the issue (e.g., Upton Sinclair’s 1904 book The Jungle played a pivotal role in awakening the public to the immense problems with the meat industry).

Eventually, in 1906, the Pure Food and Drug Act was passed, which gave the Bureau of Chemistry the authority to ensure products sold in America were accurately labeled (e.g., no hidden opium or counterfeit foods), and that the food was not adulterated.

While the publicly strongly supported this law (e.g., the public did not want to eat potentially dangerous food additives), the industry resisted and relentlessly fought Congress not to pass the law, using many of the same lines and ploys we would see today (e.g., industry lobbies would always appear to shut down any attempts to legislate against this). Eventually, it passed with the compromise that the courts would be the means to challenge enforcement actions by the law.

The director of the Bureau of Chemistry (and thus the first head of the FDA), Harvey Wiley, felt very strongly about the dangers of chemical additives being put into our foods and in 1905, began a series of tests where he gave young healthy government volunteers (e.g., those most resistant to chronic poisoning) higher doses of the additives commonly being used in foods and was able to demonstrate the recipients gradually became ill.

Now, I want to say this, because I regard it as important. For fifteen or twenty days, or even longer in some cases, no visible effects were produced in what you would call “symptoms.” The young men had normal appetites and performed their work without any discomfort, and had no complaints. After that time they began to eat their ration with some little discomfort. They were under obligation to do it, but they often said: “I wish you could let this go ; I don’t want it.” Their appetites began to fail. At the end every one of their appetites was very badly affected, and some of them were unable any longer to eat the full amount. Of course we never required anything that was impossible. They developed persistent headaches in most cases, followed by general depression and debility. It was extremely well marked in every instance.

It had a worse effect in the food when they knew it was in the food, because it became repugnant to them.

Unfortunately the effects in some cases were very much prolonged. Some of the young men—the experiments ended in July, or in June, the end of the year—and some of the young men complained even through the summer, and it was late in the autumn before they recovered their full normal appetites.

Note: the additives Wiley tested were boric acid and borax, salicylic acid (aspirin) and salicylates, benzoic acid and benzoates, sulfur dioxide and sulfites, formaldehyde, sulfate of copper (used to green produce), and saltpeter (nitrates).

In turn, a schism gradually developed in the scientific community, where Wiley (and many other respected doctors and physiologists) argued evidence showed those additives were dangerous. At the same time, a variety of scientists (who were paid off by the food industry) misleadingly testified to both Congress and then later the courts that the additives were “safe” or necessary (e.g., to prevent microbial food poisoning).

He came up and introduced himself to me [Wiley] and attempted to make some apology for his part in the activities of the Remsen Board [which was created to sabotage the FDA]. He realized very keenly the condition they were in, in espousing the cause of adulteration, becoming the paid agents of the adulterators, and incurring the universal condemnation of the press and the people of the country. Dr. Herter was then a very sick man. In a few months from that date he died.

Initially, the honest scientists (fully backed by the public) won, and Congress gave the Bureau of Chemistry the full authority to clean up the food. Still, the industry was relentless, and after failing in the courts (even in friendly jurisdictions), decided to target the executive branch directly, and successfully convinced the Secretary of Agriculture to sabotage Wiley’s work. At first, President Theodore Roosevelt vigorously opposed these efforts, and protected Wiley, but eventually he sided with the industry, and created a board (not authorized by the 1906 Food and Drug Act), which overrode everything Wiley tried to do.

Roosevelt’s about-face in turn, occurred for four key reasons.

•The food law that was passed was different from what Roosevelt had initially wanted (he wanted it to focus on meat, but the eventual meat provision that was added at the very end differed was considerably altered).

•He experienced an increasing number of complaints that the Food and Drug Act was costing industry and trading partners money.

•The Secretary of Agriculture forced Wiley to testify against Roosevelt’s position on importation taxes for Cuban sugar in front of Congress (which greatly offended Roosevelt).

•When Roosevelt was alerted to the fact Wiley wanted to remove saccharin from the marketplace (Roosevelt’s favorite sweetener), this exchange took place (which due to its consequences, tormented Wiley for decades):

This answer was the basis for the complete paralysis of the Food Law. Turning to me in sudden anger the President changed from Dr. Jekyll to Mr. Hyde, and said: “You tell me that saccharin is injurious to health?” I said, “Yes, Mr. President, I do tell you that.” He replied, “Dr. Rixey gives it to me every day.” I answered, “Mr. President, he probably thinks you may be threatened with diabetes.” To this he retorted, “Anybody who says saccharin is injurious to health is an idiot”

Note: I share this passage to illustrate how things that go catastrophically awry can often result from one unfortunate domino rippling out over decades.

In turn, while courts, state governments, legislatures, and most importantly the public supported what Wiley wanted to do, key parts of the executive branch did not. As such, his agency’s enforcement ability continually declined (e.g., virtually no enforcement actions were allowed to be brought against the thousands of cases of food adulteration they encountered), his inconvenient scientific research (e.g., on the dangers of arsenic, food colorings and preservatives in foods) was blocked from publication, partially successful attempts were made to frame him and evict him from his post (along with other types of retaliation occurring against other government employees who tried to fight for clean food), and once Taft became president in 1909, it became even more challenging for Wiley to enforce the laws (e.g., Taft overturned the ban on selling fake whiskey).

Note: in parallel to this, the Department of Agriculture created a “Bureau of Soil,” which usurped the Bureau of Chemistry’s responsibility for analyzing soil around the country (but ultimately never got anything meaningful done). This was highly problematic as it both handicapped the Bureau of Chemistry’s ability to do research, but also removed the systematic analysis of the chemistry of the nation’s soils (which was/is necessary as the trace minerals present make a considerable impact on the health of the plants and those who eat them). Likewise, another agency (the Bureau of Standards) decided it wanted to expand its influence and partnered with industry to create a variety of profitable technologies (that lay outside its Congressional mandate) while simultaneously usurping the Bureau of Chemistry’s resources and responsibilities to advance its own interests.

Eventually, in 1912, Wiley, one of the most respected public servants in the country, resigned because he realized he could do more to help the public as a private citizen than within the government and in 1927, the Bureau of Chemistry was turned into the FDA (at which point it lost the ability to do many of the critical functions it had provided to monitor the safety of the country). Far later, Wiley wrote the book “The History of A Crime Against The Food Law” (which can be read here and details much of the same abhorrent behavior we see now happening over a hundred years ago). To quote one newspaper from the time:

He [Dr. Wiley] has been practically without power to put the law into effect against strong offenders. He has been humiliated by being overruled by his subordinates. He has suffered from an inefficient administration of the Department of which his bureau is a part; for the venerable Secretary of Agriculture is too old vigorously to administer his great Department. Yet Dr. Wiley, purely for patriotic reasons, has suffered this hindrance and humiliation till some change might come which should unshackle him. On the outside the bad food and drug interests—or some of them—have maintained a lobby in Washington, have kept “syndicate” newspaper writers in their pay to write about the unfairness and the injustice of the law and the unreasonableness and “crankiness” of Dr. Wiley. One such organization—or pretended organization—some time ago sent a threatening letter to all the most important periodicals, saying that large advertisers would withdraw their patronage if they published articles favorable to the law!

To illustrate how much things remain the same, a series of investigative reports have recently shown that the lobbyists from the processed food industry are now working fervently behind the scenes to block RFK’s nomination and prevent him from reforming the industry as Secretary of HHS. Beyond the tactics being remarkably similar to what Wiley detailed the industry doing over a century ago, they also touch on a central point Wiley raised—the only way to create change in this industry is to coax the public at large to demand it, as the moment you rely upon the members of the government to fix it, lobbyists will crush those efforts. In turn, had RFK not created the Make America Healthy Again Movement and been very strategic in how he leveraged its clout, we’d never have a chance of cleaning up the food supply.
*****

****
Note. Some Links locking editor display up, use GoDuck for your reference.
*******
Medical Disclaimers apply. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Seek the assistance of health care professionals for any conditions. We are not doctors.
***Medical Disclaimers apply:: """"Forwarding, not a line by line endorsement of all items.""""" **
******

Preoperatively, 2483 (14.8%) patients reported that pain prevented any sex-life, compared to 190 patients (1.7%) at 1 year. At baseline, 14,143 of 16,729 patients (84.5%) reported that sexual activity caused pain, and among these 7232 of 10,509 responders (68.8%) reported an improvement at 1 year. A multivariable regression analysis showed that having a life partner, college education, working until time of surgery, undergoing emergency surgery, and increasing ODI score were predictors of improvement in pain during sexual activity. Increasing age, tobacco smoking, increasing body mass index, comorbidity, back pain >12 months, previous spine surgery, surgery in two or more lumbar levels, and complications occurring within 3 months were negative predictors.

This study clearly demonstrates that a large proportion of patients undergoing surgery for LDH experienced an improvement in pain during sexual activity at 1 year.

2.
2.
Retrospective review.

The aim of this study was to analyze the political contributions and strategies of the Political Action Committee (PACs) lobbying for the political interests of spine surgeons.

In 2016, a presidential election year, $514,224,628 was spent on health care lobbying. Only 16% ($85,061,148) was on behalf of health professionals providing care. Below we chronicle the overlapping contributions between the three different physician-based Political Action Committee (PAC) lobbying entities as it relates specifically to spine surgery.

Data were abstracted for the PACs of the American Association of Neurological Surgeons (AANS), American Association of Orthopedic Surgeons (AAOS), and the North American Spine Society (NASS). These data were obtained using OpenSecrets (opensecrets.org), and the Federal Election Commission (fec.gov) website. All data points were collected biannually from 2006 to 2018 and statistically analyzed as appropriate.

In 2016, the AAOS PAC contributed $2,648,218, the % of AAOS contributions and 67.9% of NASS contributions.

Spine surgery is unique in that three different physician-based lobbyist organizations seek to influence legislative priorities with the AAOS having the most substantial fiscal impact and greatest participation. Choreography of donation strategies is essential to maximize physician voice at the policy level.

5.
5.
This position paper summarizes the current understanding of the medical management of chronic pancreatitis (CP) in children in light of the existing medical literature, incorporating recent advances in understanding of nutrition, pain, lifestyle considerations, and sequelae of CP. This article complements and is intended to integrate with parallel position papers on endoscopic and surgical aspects of CP in children. Concepts and controversies related to pancreatic enzyme replacement therapy (PERT), the use of antioxidants and other CP medical therapies are also reviewed. Highlights include inclusion of tools for medical decision-making for PERT, CP-related diabetes, and multimodal pain management (including an analgesia ladder). Gaps in our understanding of CP in children and avenues for further investigations are also reviewed.
This position paper summarizes the current understanding of the medical management of chronic pancreatitis (CP) in children in light of the existing medical literature, incorporating recent advances in understanding of nutrition, pain, lifestyle considerations, and sequelae of CP. This article complements and is intended to integrate with parallel position papers on endoscopic and surgical aspects of CP in children. Concepts and controversies related to pancreatic enzyme replacement therapy (PERT), the use of antioxidants and other CP medical therapies are also reviewed. Highlights include inclusion of tools for medical decision-making for PERT, CP-related diabetes, and multimodal pain management (including an analgesia ladder). Gaps in our understanding of CP in children and avenues for further investigations are also reviewed.
The aim of the study was to assess the efficacy, safety and side-effect profile of ferric carboxymaltose (FCM) for correcting IDA in children and adolescents in paediatric gastroenterology, hepatology, and nutrition.

This was a retrospective study of all gastroenterology patients <18 years who had FCM (October 2015 to October 2017). Haematological and biochemical parameters were recorded pre-infusion, at 4 weeks, 3 months, 6 months, and 1 year post-infusion. Recognised side-effects were documented.

Sixty-six children received FCM during this period. Data was analysed on 61 children, 5 excluded because of inadequate data. The median age at administration was 14 years (IQR 7). Thirty-two (52%) were boys. Twenty-six (42%) were <14 years old. https://www.selleckchem.com/products/gsk2830371.html Seven (11.5%) were <5 years old. Seventeen (28%) were switched from oral iron supplements to FCM. The median dose of FCM delivered was 19 mg/kg. The median haemoglobin increased from 108 to 126 g/L at 1 month post-infusion (P value <0.00001). The mean cell volume also improved from 80 to 84 fL at 1 month post-infusion (P value = 0.0007). Forty-eight (94%) children corrected their anaemia after receiving FCM. Two patients (3%) reported side-effects with skin bruising and staining.

FCM appears to be effective in correcting IDA in children across a wide range of gastroenterology indications and all ages. It is effective and generally well tolerated including in very young patients. Potential side-effects can be avoided by careful monitoring during infusions.
FCM appears to be effective in correcting IDA in children across a wide range of gastroenterology indications and all ages. It is effective and generally well tolerated including in very young patients. Potential side-effects can be avoided by careful monitoring during infusions.
The incidence and prevalence of eosinophilic esophagitis (EoE) and inflammatory bowel disease (IBD) are rising with similar patterns. Co-occurrence of both diseases in the same patient has been increasingly reported. We sought to examine the pediatric population with both EoE and IBD to better understand the epidemiology and clinical implications of this overlap.

We conducted a retrospective case-control study at 2 tertiary care children's hospitals. Subjects with both EoE and IBD were identified and compared with randomly selected controls with EoE and IBD alone in terms of demographics, atopic conditions, IBD classification, location and phenotype of Crohn disease (CD), IBD medications, endoscopic findings, and histopathology. Descriptive statistics summarized the data.

Sixty-seven subjects with dual-diagnosis were identified across both institutions. The prevalence of IBD in the EoE population was 2.2% and EoE in IBD was 1.5%. Subjects with both diseases were more likely to have IgE-mediated food allergy compared with IBD alone (36% vs 7%, P < 0.

Election judge in Minnesota sued for allowing unregistered people to vote

https://newstarget.com/2024-11-29-election-judge-minnesota-sued-accepting-unregistered-votes.html